cannabisbusinessinsights.comAUGUST-SEPTEMBER 20256Elevating Care through Cannabis InnovationAs patient expectations evolve as the limitations of conventional treatments become increasingly evident, medicinal cannabis is shifting from alternative therapy to a central component of modern, patient-centered care. Across clinical settings, specialized cannabis therapeutics are now essential tools in managing chronic pain, neurological disorders, oncology symptoms and mental health conditions.To meet this growing demand, leading medicinal cannabis organizations follow precision cultivation, pharmaceutical-grade formulation, rigorous testing, clinical education and ongoing patient support.Technology accelerates this growth. AI-powered dosing engines, real-world evidence platforms and digital engagement tools enable more personalized treatment, continuous monitoring and measurable improvements in therapeutic outcomes. These innovations give healthcare providers greater confidence in prescribing and help patients receive care that is data-driven and tailored to their individual needs.This edition of Cannabis Business Insights APAC explores how high-performing medicinal cannabis organizations are transforming integrative care into a disciplined, technology-enabled and outcomes-focused field.Featured thought leaders include Wataru Momose, director of anti-tuberculosis project (Global TB project) at Otsuka Pharmaceutical Co., Ltd., who highlights the integration of AI, preventive care and continuous production systems in biopharmaceutical manufacturing as key strategies for reducing medical costs and improving quality of life. Raymond R. Tjandrawinata, director of business development and scientific affairs at DexaMedica, advocates a quality assurance approach built on certified sourcing, rigorous testing, traceable documentation and adherence to international standards.The magazine also spotlights leaders like CANNFX (by Ampyl Sciences), a New Zealand­based medicinal cannabis brand, exporting high-grade, non-irradiated dried flower globally. Partnered with top cultivators, it ensures certified quality and consistent pharmacological standards.We hope this edition offers valuable insight into how medicinal cannabis is reshaping the future of clinical care, expanding treatment options and raising the standard for patient outcomes.Let us know your thoughts!EDITORIAL STAFFAva GarciaDavies MedowsJohnson HellerJoshua Parkersales@cannabisbusinessinsights.comeditor@cannabisbusinessinsights.commarketing@cannabisbusinessinsights.comEmailVISUALIZERSDisclaimer: *Some of the Insights are based on our interviews with CIOs and CXOsMANAGING EDITORCannabis Business Insights Visit www.cannabisbusinessinsights.comCopyright © 2025 ValleyMedia, Inc. All rights reserved. Reproduction in whole or part of any text, photography or illustrations without written permission from the publisher is prohibited. The publisher assumes no responsibility for unsolicited manuscripts, photographs or illustrations. Views and opinions expressed in this publication are not necessarily those of the magazine and accordingly, no liability is assumed by the publisher thereof.AUGUST-SEPTEMBER 2025, Vol - 03, Issue - 06 (ISSN 2837-1658) Published by ValleyMedia, Inc. TO SUBSCRIBE TOVian Isaac600 S Andrews Ave Ste 405, Ft Lauderdale, Fl 33301EDITORIALLouis PeterLouis PeterManaging Editoreditor@cannabisbusinessinsights.comCelestial JordanOlivia SmithBUSINESS SERVICES FOR CANNABIS INDUSTRYAPACAPAC
< Page 5 | Page 7 >